WISSENSCHAFTLICHE PUBLIKATIONEN

Privatdozent Dr. med. Dr. med. habil. Georg Reimer

  Text-Download als PDF-Datei

  1. Reimer, G.
    (1982)   Tumorförmige Tuberculois cutis luposa. Aktuelle Dermatologie 8, 26-28.
    2.  
  2. Reimer,  G. and D. Djawari
    (1982)   Lymphocytotxicity for oral epithelial cells in Behcet´s disease. A case report. Dermatologica 164, 82-89.
    3.  
  3. Reimer, G.
    (1982)   Zur Klinik und Immunpathologie des Morbus Behcet. Deutsche Zeitschrift für Mund-Kiefer-Gesichtschirurgie 6, 174-178.
    4.  
  4.  Reimer, G., S. Steinkohl, D. Djawari and O.P. Hornstein (1982)   Lytic effect of cytotoxic lymphocytes on oral epithelial cells in Behcet´s disease.  British Journal of Dermatology 107, 529-536.
    5.  
  5. Reimer, G., I. Link und H. Hauck
    (1982)    Senear-Usher-Syndrom: Begleithämophilie durch das Auftreten eines Faktor VIII Hemmkörpers. Der Hautarzt 34, 645-648.
    6.  
  6. Deinlein, E., G. Reimer, U. Huschka und S. Rios-Arizpe
    (1982)   Immunpathologische Untersuchungen bei Herpes gestationis. Der Hautarzt 34, 6-9.
    7.  
  7. Simon, M., jr., F. Unterpaintner und G. Reimer
    (1982)   Immunphänomene bei Lichen ruber – eine immunfluoreszenzmikroskopische Studie. Zeitschrift für Hautkrankheiten 58, 121-128.
    8.  
  8. Reimer, G. and D. Djawari
    (1983)   Lymphocytotoxicity for oral epithelial cells in Behcet´s disease. In:  International Synopsis. Dermatology Digest/March 1982, 4.
    9.  
  9. Reimer, G. und M. Simon jr. (1983)   Lymphozytotoxizität bei Lichen planus der Mundschleimhaut. Der Hautarzt. Supplementum VI, 32, 238.
    10.  
  10. Reimer, G., U. Huschka und J. Keller  (1983)   Epidermale nukleäre Immunglobulin-Ablagerungen bei progressiver Sklerodermie. Der Hautarzt. Supplementum, VI, 34.237.
    11.  
  11. Simon, M. jr., F. Unterpaintner und G. Reimer
    (1983)   Immunphänomene bei Lichen ruber. Der Hautarzt. Supplementum VI, 34, 298.
    12.  
  12. Simon, M. jr., G. Reimer, M. Schardt and O.P. Hornstein
    (1983)   Lymphocytotoxicity for oral epithelial mucosa in lichen planus. Dermatologica 167, 11-15.
    13.  
  13. Reimer, G., U. Huschka, J. Keller, R. Kammerer and O.P. Hornstein
    (1983) Immunofluorescence studies in progressive systemic sclerosis (scleroderma) and mixed connective tissue disease. British Journal of Dermatology 109, 27-36.
    14.  
  14. Reimer, G., L. Luckner and O.P. Hornstein
    (1983)  Direct immunofluorescence in recurrent aphthous ulcers and Behcet´s disease. Dermatologica 167, 293-298.
    15.  
  15. Reimer, G., G. Liebel and O.P. Hornstein
    (1984)   In vitro complement  activation by antinuclear antibodies in the epidermis from patients with systemic sclerosis. British Journal of Dermatology 110, 169-174.
    16.  
  16. Reimer, G., R.L. Rubin, B.L. Kotzin and E.M. Tan
    (1984)  Anti-native DNA antibodies from autoimmune sera also bind to DNA in mitochondria. Journal of Immunology 133, 2532-2536.
    17.  
  17. Rubin, R.L., G. Reimer, E.M. McNally, S.R. Nusinow, R.P. Searles and E.M. Tan
    (1986)  Procainamide elicits a selective autoantibody immune response. Clinical and Experimental Immunology 63, 58-67.
    18.  
  18. Reimer, G., U. Scheer, J.-M. Peters and E.M. Tan
    (1986)  Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyosits/scleroderma overlap syndromes. Journal of Immunology 137, 3802-2808.
    19.  
  19. Reimer, G., K.M. Rose, U. Scheer and E.M. Tan  (1987) Autoantibody to RNA polymerase I in scleroderma sera. Journal of Clinical Investigation 79, 65-72.
    20.  
  20. Reimer, G., K.M. Pollard, C.A. Penning, R.L. Ochs, M.A. Lischwe, H. Busch and E.M. Tan (1987)  Monoclonal antibody from a (New Zealand black x New Zealand white) F1 mouse and some human scleroderma sera target a Mr 34,000 nucleolar protein of the U3-ribonucleoprotein particle. Arthritis and Rheumatism 30, 794-800.
    21.  
  21. Reimer, G., R.C.Cornell and E.M. Tan (1987)   The biochemical nature of antigens reactive with antinuclear antibodies. In: Immunopathology of the Skin (Beutner, E.H., T.P.Chorzelski and V.K.Kumar editors), 3rd edition . Wiley Medical Publication, 519-531.
    22.  
  22. Reimer, G. and E.M. Tan (1987)  Antinuclear antibodies. In: Internal Medicine (Stein, J.H. Editor-in-Chief), 2nd edition. Little, Brown and Company Medical Division, pp 1200-1204.
    23.  
  23. Tan, E.M., G. Reimer and K. Sullivan (1987) Intracellular autoantigens: diagnostic fingerprints but etiological dilemmas. Chichester (Ciba Geigy Foundation Symposium), 25-42.
    24.  
  24. Reimer, G. (1987)   Nukleoläre Autoantigene bei progressiver Sklerodermie – Makromolekulare Charakterisierung und klinische Bedeutung. Habilitationsschrift. Friedrich-Alexander-Universität, Erlangen-Nürnberg.
    25.  
  25. Reimer, G.  (1987)    Zellkernantigene bei systemischen Autoimmunerkrankungen: Molekulare Charakteristika und klinische Bedeutung. Zentralblatt für Haut- und Geschlechtskrankheiten 153, 789-800.
    26.  
  26. Benavente, R., K.M. Rose, G. Reimer, B. Hügle-Dörr and U. Scheer (1987)   Inhibition of nucleolar reformation after microinjection of antibodies to RNA polymerase I into mitotic cells. Journal of Cell Biology 105, 1843-1491.
    27.  
  27. Reimer, G., I. Raska, E.M. Tan and U. Scheer (1987)  Human autoantibodies: probes for nucleolus structure and function. Virchows Archiv B 54, 131-143.
    28.  
  28. Reimer, G. (1988)   Zellkernantigene bei systemischen Autoimmunerkrankungen. In: Neue Entwickelungen in der Dermatologie (Hornstein, O.P., Hundeiker, M. und J. Schönfeld Herausgeber). Springer Verlag, 12-23.
    29.  
  29. Reimer, G., V.D. Steen, C.A. Penning, T.A. Medsger and E.M. Tan (1988)   Correlates between antibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis and Rheumatism 31, 525-532.
    30.  
  30. Reimer, G., I. Raska, U. Scheer and E.M.Tan (1988)  Immunolocalization of 7-2 ribonucleoprotein in the granular component of the nucleolus. Experimental Cell Research 176, 117-125.
    31.  
  31. Haaf, T., G. Reimer and M. Schmid (1988)   Immunocytogenetics: I. Localization of transcriptionallly active rRNA genes in nucleoli and nucleolus organizer regions by human autoantibodies to RNA polymerase I. Cytogenetics and Cell Genetics 48, 35-42.
    32.  
  32. Benavente, R., M.S. Schmidt-Zachmann, B. Hügle-Dörr, G. Reimer, K.M. Rose and U. Scheer (1988)  Identification and definition of nucleolar-realted fibrillar bodies in micronucleated cells. Experimental Cell Research 178, 518-523.
    33.  
  33. Benavente, R., G. Reimer, K.M. Rose, B. Hügle-Dörr and U. Scheer (1988)   Nucleolar changes after microinjection of antibodies to RNA polymerase I into the nucleus of mammalian cells. Chromosoma 97, 115-123.
    34.  
  34. Raska, I., G. Reimer, M. Jarnik, Z. Kostrouch and K. Raska, jr. (1989)   Does the synthesis of ribosomal RNA take place within nucleolar centers or dense fibrillar components? Biology of the Cell 65, 79-82.
    35.  
  35. Pollard, K.M., G. Reimer and E.M. Tan (1989)  Autoantibodies in scleroderma. Clincal and Experimental Rheumatology 7/S-3, 57-62.
    36.  
  36. Reimer, G. (1990)  Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma). In: Rheumatic Diseases Clinics of North America. W.B. Saunders Company, Philadelphia, Vol.16. No.1, 169-183.
    37.  
  37. Kurzhals, G,  M. Meurer, Th. Krieg and G. Reimer (1990)   Clinical association of autoantibodies to fibrillarin with diffuse scleroderma and disseminated teleangiectasia. Journal of the American Academy of Dermatology 23, 832-836.
    38.  
  38. Piccinini, G., E. Gardellini, G. Reimer, F.C. Arnett and E. Durban (1991)  An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodes of scleroderma patients. Molecular Immunology 28, 333-339.
    39.  
  39. Reimer, G., and E.M. Tan (1993)   Systemic sclerosis (scleroderma) and mixed connective tissue disease. In: Clinical Aspects of Immunology (Lachmann, P., D.K. Peters, F.S. Rosen and M.J. Walport editors). Fifth edition. Blackwell Scientific Publications,  1241-1258
    40.  
  40. Pollard, K.M. und G. Reimer (1996)  Humorale, genetische und umweltassoziierte Aspekte der Sklerodermieforschung. Aktuelle Rheumatologie 21, 167-170.
    41.  
  41. Futura, K., E.K.L Chan, K. Kiyosawa, G. Reimer, C. Luderschmidt and E.M. Tan (1997)   Heterochromatin protein HP1Hsß (p25ß) and its localization with centromeres in mitosis. Chromosoma 106, 11-19.
    42.  
  42. Futura, K., B. Hildebrandt, S. Matsuoka, K. Kiyosawa, G. Reimer, C. Luderschmidt, E.K.L. Chan and E.M. Tan  (1998)  Immunological characterization of heterochromatin p25ß autoantibodies and relationship with centromere autoantibodies and pulmonary fibrosis in systemic scleroderma. Journal of Molecular Medicine 76, 54-60.
    43.  
  43. Raska I. and G. Reimer (1999)  Human autoantibodies identify a protein in dense fibrillar and granular components of the nucleolus. Acta histochemica 101, 157-166.
    44.  
  44. Percipalle, P., N. Fomproix, E. Cavellan. R. Voit, G. Reimer, T. Krüger, J. Thyberg, U. Scheer, I. Grummt and A.-K. Östlund Farrants (2006)   The chromatin remodelling complex WSTF-SNF2h interacts with nuclear myosin1 and has a role in RNA polymerase I transcription. EMBO reports 7, 525-530.
    45.  
  45. Reimer, G., Brudler, O., Heinrich, B. und M. Bangerter (2008) (2006)  EGFR-Blocker bremsen Tumorwachstum, aber: In vier von fünf Fällen reagiert auch die Haut. InIFoOnkologie 11, 281-283 (Nr. 4)
    46.  
  46. Reimer, G., Brudler, O., Heinrich, B., und M. Bangerter (2008) (2006)  Nebenwirkungen der EGFR-Blockade. Hautschutz gehört mit zur Therapie. MMW-Fortschr.Med. Nr. 49-50, 37-40.
    47.  
  47. Reimer, G., Brudler, O., Heinrich, B., und M. Bangerter (2009) (2006)  Nebenwirkungen der EGFR-Blockade. Hautschutz gehört mit zur Therapie. hautnah dermatologie 2,68-70.
    48.  
  48. Gutzmer, R., Becker, J.C., Enk, A., Garbe, C., Hauschild, A., Leverkus, M., Reimer, G., Treudler, R., Tsianakas, A., Ulrich, C., Wollenber, A. und B. Homey (2011) (2006)  Management kutaner Nebenwirkungen von EGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremium für den primär behandelnden Arzt. J.Dtsch Dermatol Ges. 9(3): 195-203.